We are proud to share a major milestone for paediatric brain cancer research: the TarGeT clinical trial is now open at both The Royal Children’s Hospital, Melbourne and Perth Children’s Hospital, with the first patient officially enrolled.

TarGeT is a precision-medicine clinical trial for children with high-grade gliomas, representing a significant step forward in expanding access to innovative, targeted therapies across Australia and New Zealand. The opening of the trial marks years of collaborative effort from researchers, clinicians, hospital teams and funding partners working together to improve outcomes for children and families facing these devastating diagnoses.

The Robert Connor Dawes (RCD) Foundation is proud to be part of the TarGeT Collaborative, alongside Children’s Cancer Foundation, My Room Children’s Cancer Charity, The Kids’ Cancer Project, the Mark Hughes Foundation Centre for Brain Cancer Research, and The Cure Starts Now Cancer Foundation. Together, these organisations share a commitment to accelerating progress in paediatric brain cancer research through collaboration, innovation and shared purpose.

We congratulate ANZCHOG, the investigators, research teams and hospital staff whose dedication has brought TarGeT to life, and we look forward to the impact this trial will have for children and families now and into the future.